Equities Analysts Set Expectations for Reata Pharmaceuticals, Inc.’s Q3 2017 Earnings (RETA)
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) – Jefferies Group issued their Q3 2017 earnings estimates for Reata Pharmaceuticals in a note issued to investors on Wednesday. Jefferies Group analyst M. Raycroft anticipates that the company will post earnings of ($0.40) per share for the quarter. Jefferies Group has a “Buy” rating and a $44.00 price target on the stock. Jefferies Group also issued estimates for Reata Pharmaceuticals’ Q4 2017 earnings at ($0.41) EPS, FY2017 earnings at ($1.65) EPS, FY2018 earnings at ($2.19) EPS, FY2019 earnings at ($3.05) EPS, FY2020 earnings at ($0.37) EPS and FY2021 earnings at ($0.78) EPS.
A number of other equities research analysts have also recently commented on RETA. Citigroup Inc. reiterated a “buy” rating and issued a $78.00 price target (down from $87.00) on shares of Reata Pharmaceuticals in a research note on Wednesday, August 23rd. ValuEngine raised Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, May 27th. Stifel Nicolaus reaffirmed a “buy” rating and set a $50.00 target price (up from $38.00) on shares of Reata Pharmaceuticals in a report on Tuesday, July 25th. Robert W. Baird reaffirmed an “outperform” rating and set a $47.00 target price (up from $43.00) on shares of Reata Pharmaceuticals in a report on Tuesday, July 25th. Finally, Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $61.00 target price (up from $55.00) on shares of Reata Pharmaceuticals in a report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $52.86.
Shares of Reata Pharmaceuticals (NASDAQ RETA) opened at 30.25 on Friday. Reata Pharmaceuticals has a 12-month low of $18.08 and a 12-month high of $41.60. The company’s market capitalization is $789.62 million. The company has a 50-day moving average price of $29.42 and a 200 day moving average price of $26.49.
Several hedge funds have recently bought and sold shares of the stock. Nationwide Fund Advisors increased its stake in Reata Pharmaceuticals by 38.1% in the second quarter. Nationwide Fund Advisors now owns 4,368 shares of the company’s stock valued at $138,000 after buying an additional 1,206 shares in the last quarter. Wells Fargo & Company MN boosted its position in Reata Pharmaceuticals by 37.4% in the second quarter. Wells Fargo & Company MN now owns 5,591 shares of the company’s stock valued at $176,000 after buying an additional 1,521 shares during the last quarter. Teachers Advisors LLC boosted its position in Reata Pharmaceuticals by 12.8% in the fourth quarter. Teachers Advisors LLC now owns 10,116 shares of the company’s stock valued at $221,000 after buying an additional 1,148 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Reata Pharmaceuticals by 102.4% in the second quarter. The Manufacturers Life Insurance Company now owns 7,343 shares of the company’s stock valued at $233,000 after buying an additional 3,715 shares during the last quarter. Finally, Virtu KCG Holdings LLC acquired a new position in Reata Pharmaceuticals during the second quarter valued at about $249,000. 21.85% of the stock is owned by institutional investors and hedge funds.
In other Reata Pharmaceuticals news, major shareholder A/S Novo sold 61,000 shares of Reata Pharmaceuticals stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $25.11, for a total transaction of $1,531,710.00. Following the completion of the sale, the insider now directly owns 642,405 shares of the company’s stock, valued at approximately $16,130,789.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James Edward Bass purchased 8,064 shares of the firm’s stock in a transaction on Tuesday, August 1st. The shares were acquired at an average cost of $31.00 per share, with a total value of $249,984.00. Following the completion of the acquisition, the director now directly owns 67,411 shares in the company, valued at $2,089,741. The disclosure for this purchase can be found here. Insiders have sold a total of 471,886 shares of company stock valued at $12,541,056 over the last three months. 62.40% of the stock is currently owned by insiders.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.